Trial record 5 of 5 for:
TIVOZANIB | Renal Cancer | Italy
Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma (CASSIOPE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03419572 |
|
Recruitment Status :
Recruiting
First Posted : February 5, 2018
Last Update Posted : February 24, 2021
|
Sponsor:
Ipsen
Information provided by (Responsible Party):
Ipsen
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms of dose modifications due to adverse events (AEs) when used as a second line therapy or third and later line therapy. Other patterns of use of cabozantinib will also be described.
| Condition or disease | Intervention/treatment |
|---|---|
| Renal Cell Carcinoma | Other: Data collection |
The study will follow the real-life management of patients in clinical practice. Visits will take place according to the study site's clinical practice. Cabozantinib is to be administered as directed by the investigator according to the study site's usual clinical practice and the Cabometyx™ Summary of Product Characteristics (SmPC).
| Study Type : | Observational |
| Estimated Enrollment : | 680 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy |
| Actual Study Start Date : | April 24, 2018 |
| Estimated Primary Completion Date : | April 30, 2021 |
| Estimated Study Completion Date : | April 30, 2021 |
Resource links provided by the National Library of Medicine
| Group/Cohort | Intervention/treatment |
|---|---|
|
Second line therapy
Data collection
|
Other: Data collection
Only available evaluations as decided by the investigator based on local clinical practice will be collected. |
|
Third and later line therapy
Data collection
|
Other: Data collection
Only available evaluations as decided by the investigator based on local clinical practice will be collected. |
Primary Outcome Measures :
- The proportion of subjects with dose modifications due to AEs [ Time Frame: 12 months ]
Secondary Outcome Measures :
- Reason for cabozantinib dose modification (any modification, reduction, temporary interruption or discontinuation) [ Time Frame: 12 months ]Percentage of subjects with the following reasons - Disease progression, Adverse event, Subject non-compliance, Treatment resumed or re escalated, Subject decision, Clinical / investigator decision, Other
- Description of number of cabozantinib dose modifications (any modification, reduction, temporary interruption, increase or discontinuation) [ Time Frame: 12 months ]
- Median time to first cabozantinib dose modification (any modification, reduction, temporary interruption, increase or discontinuation) due to AEs and for any reason [ Time Frame: 12 months ]
- Description of cabozantinib starting dose (combination of dose per intake and frequency) [ Time Frame: 12 months ]
- Description of daily dose of cabozantinib received [ Time Frame: 12 months ]
- Description of cabozantinib dose intensity (average daily dose compared to starting dose) [ Time Frame: 12 months ]
- Duration of cabozantinib treatment (expressed as mean and median time to end of treatment) [ Time Frame: 12 months ]
- Proportion of subjects with concomitant radiotherapies [ Time Frame: 12 months ]
- Description of systemic therapy (drug name) planned following cabozantinib discontinuation [ Time Frame: 12 months ]Percentage of subjects treated with the following drugs: Sunitinib, Pazopanib, Axitinib, Sorafenib, Bevacizumab, Cytokines, Everolimus, Lenvatinib, Nivolumab, Tivozanib, Experimental trial drug, Other, Unknown)
- Overall best response [ Time Frame: 12 months ]Per investigator assessment
- Median Progression Free Survival (PFS) time [ Time Frame: 12 months ]Defined as the time between the start date of cabozantinib and the date of progression or death. Clinical and radiographic (assessed by the investigator based on RECIST 1.1)
- Overall Survival (OS) rate at the end of the study [ Time Frame: 12 months ]
- Health care resource utilisation: number of visits to health care professionals (hospitalisation, surgical procedure, emergency room, physician, homecare by nurse) associated with the management of treatment-related AEs [ Time Frame: 12 months ]
- Health care resource utilisation: Description of concomitant medications (by drug class and preferred name) associated with the management of treatment-related AEs [ Time Frame: 12 months ]
- Health care resource utilisation: Description of number of unplanned laboratory tests associated with the management of treatment-related AEs [ Time Frame: 12 months ]
Other Outcome Measures:
- Incidence of all treatment-emergent non-serious and serious AEs [ Time Frame: 12 months ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Subjects with advanced RCC following prior VEGF-targeted therapy in real life settings.
Criteria
Inclusion Criteria:
- Age ≥18 years old
- Has a diagnosis of advanced RCC
- Has received at least one prior VEGF-targeted therapy
- For whom the treating physician has decided to start treatment with cabozantinib tablets prior to inclusion
- No previous exposure to cabozantinib prior to inclusion
- Not concurrently involved in an interventional study
- Consents to participate in this noninterventional study
Exclusion Criteria:
- There are no exclusion criteria for this study.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03419572
Contacts
| Contact: Ipsen Recruitment Enquiries | see email | clinical.trials@ipsen.com |
Locations
Show 108 study locations
Sponsors and Collaborators
Ipsen
Investigators
| Study Director: | Ipsen Medical Director | Ipsen |
| Responsible Party: | Ipsen |
| ClinicalTrials.gov Identifier: | NCT03419572 |
| Other Study ID Numbers: |
F-FR-60000-001 EUPAS19464 ( Registry Identifier: EU PAS Register ) |
| First Posted: | February 5, 2018 Key Record Dates |
| Last Update Posted: | February 24, 2021 |
| Last Verified: | February 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Carcinoma, Renal Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Kidney Neoplasms Urologic Neoplasms |
Urogenital Neoplasms Neoplasms by Site Kidney Diseases Carcinoma Adenocarcinoma Urologic Diseases |